Pfizer Offers Dividend Opportunity

Morningstar's Damien Conover expects steady growth for the pharmaceutical firm, which will likely lead to steady growth for the dividend

Damien Conover, CFA 7 June, 2017 | 12:23PM
Facebook Twitter LinkedIn

 

Damien Conover: When thinking about dividends, Pfizer (PFE) offers a great opportunity for investors. We think the stock is undervalued and pays a very strong dividend. Right now, the dividend yield is close to 4%. That dividend is really supported by a strong portfolio of drugs--a lot of new drugs coming into the portfolio and really not too many patent losses in the near term. So, we're anticipating relatively steady growth for the firm, and that will likely transfer into steady growth for the dividend.

When we think about its peer group, most of the large-cap pharmaceutical stocks pay out about 50% of their earnings in a dividend. Pfizer is right there with that group, and we think that will likely stay the case for the next several years. So, as earnings continue to grow, we think the dividend will grow modestly as well.

Thinking about historically, Pfizer's dividend has been very secure; however, when they did buy Wyeth back several years ago, they did cut the dividend. Now, we think that was largely due to a lot of the cash that they needed to fund that acquisition. Going forward, we expect Pfizer to make an acquisition of a larger size, but we don't anticipate a dividend cut. Now, a lot of the reasons for that is the balance sheet is very secure and the earnings are relatively stable.

So, when we think about the context of not only strong dividend, but from a valuation perspective, we think the stock is undervalued as well. So, we are looking at a firm that has a good total return for investors. On top of that, this is a firm that we see as having a wide economic moat, supported by a lot of drugs, both currently marketed as well as next-generation molecules out there for Pfizer.

When we think about risks to the overall equation, sometimes drug pricing pressure comes up. We believe that Pfizer's drug portfolio is well-positioned for that. A lot of complex molecules, molecules serving the more specialty-oriented group. That group tends to have stronger pricing power, and we think that will not only support earnings growth but also a secure dividend for the near and long term.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Pfizer Inc25.40 USD0.55Rating

About Author

Damien Conover, CFA  is an equity analyst and associate director at Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures